About Nitika Pharmaceutical Specialities Private Limited
Data last updated: 22 February 2026
Nitika Pharmaceutical Specialities Private Limited is a private limited company based in Nagpur, Maharashtra, India. It specialises in industrial chemicals, a part of the broader chemicals and materials sector. Incorporated on 12 March 2011, the company has been in operation for over 15 years.
Registered with ROC Nagpur under CIN U24230MH2011PTC214662.
Capital: an authorised share capital of ₹9.5 Cr and a paid-up capital of ₹3.14 Cr. Formerly known as Nitika Pharma Specialities Private Limited. It is led by directors including Ravleen Singh Khurana and Manojkumar Badrinarayan Agrawal.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Nagpur, Maharashtra.
As per the financials filed for FY 2024, the company reported a revenue of ₹80.91 Cr, a growth of 35% compared to the previous year.
The company has a workforce of approximately 122 employees as per the latest available data.
The company is associated with 1 brand - Nitika Pharmaceuticals. As per MCA filings, the company has open charges of ₹180.53 Cr and satisfied charges of ₹20.77 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nitikapharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressFortune Ritz F. No. 101 Pl. 240/A, Near Raja Rani Square Civil Lines, Nagpur, Maharashtra, India – 440001
-
IndustryChemicals and Materials, Industrial Chemicals
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Nitika Pharmaceutical Specialities Private Limited
Nitika Pharmaceutical Specialities Private Limited operates one associated brand: Nitika Pharmaceuticals. These brands represent Nitika Pharmaceutical Specialities Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturing of pharmaceutical excipients, antacid actives, and mineral salts in India. | nitikapharma.com |
Business Activity of Nitika Pharmaceutical Specialities Private Limited
Nitika Pharmaceutical Specialities Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Nitika Pharmaceutical Specialities Private Limited
Nitika Pharmaceutical Specialities Private Limited is audited by BHASIN DATAR ASSOCIATES for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| BHASIN DATAR ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of Nitika Pharmaceutical Specialities Private Limited
Nitika Pharmaceutical Specialities Private Limited is currently managed by 3 directors, with 5 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ravleen Singh Khurana | Director | 12 Mar 2011 | 15 Years 3 Months | Current |
|
Manojkumar Badrinarayan Agrawal
Also directs:
Infill Life Sciences Llp
|
Director | 10 Jul 2018 | 7 Years 11 Months | Current |
| Parvinder Singh | Director | 11 Jul 2019 | 6 Years 11 Months | Current |
Financials of Nitika Pharmaceutical Specialities Private Limited FY 2024 filings available
Nitika Pharmaceutical Specialities Private Limited reported revenue of ₹80.91 Cr (up 35% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Nitika Pharmaceutical Specialities Private Limited
As of FY 2023, Nitika Pharmaceutical Specialities Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Nitika Pharmaceutical Specialities Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Jul 2025 | Bank of India | ₹3 Cr | Open |
| 30 May 2025 | Others | ₹100 Cr | Open |
| 12 Dec 2023 | Bank of India | ₹35 Cr | Open |
| 22 Mar 2022 | Axis Bank Limited | ₹42.19 Cr | Open |
| 27 Nov 2020 | Hdfc Bank Limited | ₹34 Lakh | Open |
Total charge records: 10 View all charges
Employees and EPFO Compliance at Nitika Pharmaceutical Specialities Private Limited
Nitika Pharmaceutical Specialities Private Limited has a workforce of 122 employees as of Dec 14, 2024.
Employee Count & EPFO Data of Nitika Pharmaceutical Specialities Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Nitika Pharmaceutical Specialities Private Limited
GSTIN & GST Filing Data of Nitika Pharmaceutical Specialities Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Nitika Pharmaceutical Specialities Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Nitika Pharmaceutical Specialities Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Nitika Pharmaceutical Specialities Private Limited
MSME Payment Delays by Nitika Pharmaceutical Specialities Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Nitika Pharmaceutical Specialities Private Limited
Subsidiaries & Group Companies of Nitika Pharmaceutical Specialities Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Nitika Pharmaceutical Specialities Private Limited with ownership details.
MCA Filings & Documents of Nitika Pharmaceutical Specialities Private Limited
MCA Filings & Documents of Nitika Pharmaceutical Specialities Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Nitika Pharmaceutical Specialities Private Limited
Frequently Asked Questions about Nitika Pharmaceutical Specialities Private Limited
Nitika Pharmaceutical Specialities Private Limited is an active private limited company in the chemicals and materials sector based in Nagpur, Maharashtra, India. It was incorporated on 12 March 2011 (15+ years old) and is registered under CIN U24230MH2011PTC214662. The company has 122 employees.
Nitika Pharmaceutical Specialities Private Limited reported revenue of ₹80.91 Cr for FY 2024 (up 35.00% YoY).
The current directors of Nitika Pharmaceutical Specialities Private Limited are:
The primary industry of Nitika Pharmaceutical Specialities Private Limited is chemicals and materials. The company specifically operates in industrial chemicals. The company is currently active in this sector.
Nitika Pharmaceutical Specialities Private Limited can be reached at the registered office: Fortune Ritz F. No. 101 Pl. 240A, Near Raja Rani Square Civil Lines, Nagpur, Maharashtra, India – 440001, or through the website nitikapharma.com.
The authorised capital is ₹9.5 Cr, and the paid-up capital is ₹3.14 Cr.